All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
31 - 40 of 45 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Presentation
An open-label, Phase Ib trial of the SIRPα inhibitor BI 765063 in combination with the PD-1 inhibitor ezabenlimab and cetuximab in patients with head and neck squamous cell carcinoma
Author(s): Rojas et al.
An open-label, Phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors
Author(s): Wang et al.
Phase I trial of DLL3/CD3 IgG-like T-cell engager obrixtamig (BI 764532) in patients with DLL3-positive tumours: patients with LCNEC-L
Author(s): Wermke et al.
Target Engagement and Saturating Effects demonstrated with quantitative 89Zr-PET imaging for the Therapeutic Anti-SIRPα Antibody BI 765063
Author(s): Pouw et al.
Infographic
DAREON®-NEC-1: Phase III trial of first-line (1L) obrixtamig plus carboplatin and etoposide (SoC) vs SoC in patients with delta-like ligand 3 (DLL3)-positive extrapulmonary neuroendocrine carcinoma (epNEC)
Author(s): Vandamme et al.
DAREON®-Lung-1: Phase III trial of first-line obrixtamig plus standard of care (atezolizumab, carboplatin, and etoposide) versus standard of care in ES-SCLC
Author(s): Leal et al.
Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas of genitourinary origin with high or low DLL3 expression: results from an ongoing Phase I trial
Author(s): Navarro-Gorro et al.
DAREON®-7: Phase I open-label dose-escalation/-expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas
Author(s): Chauhan et al.
An ongoing Phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression
Author(s): Capdevila et al.
An open-label, Phase Ib trial to assess the safety and efficacy of SIRPα monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852)
Author(s): Laban et al.